IN2014MN01484A - - Google Patents
Info
- Publication number
- IN2014MN01484A IN2014MN01484A IN1484MUN2014A IN2014MN01484A IN 2014MN01484 A IN2014MN01484 A IN 2014MN01484A IN 1484MUN2014 A IN1484MUN2014 A IN 1484MUN2014A IN 2014MN01484 A IN2014MN01484 A IN 2014MN01484A
- Authority
- IN
- India
- Prior art keywords
- composition
- ingredients
- insulin
- acylated
- level
- Prior art date
Links
- 239000000203 mixture Substances 0.000 abstract 4
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical class N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 abstract 3
- 102000015636 Oligopeptides Human genes 0.000 abstract 2
- 108010038807 Oligopeptides Proteins 0.000 abstract 2
- 239000004615 ingredient Substances 0.000 abstract 2
- 208000002249 Diabetes Complications Diseases 0.000 abstract 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 abstract 1
- 102000004877 Insulin Human genes 0.000 abstract 1
- 108090001061 Insulin Proteins 0.000 abstract 1
- 239000013543 active substance Substances 0.000 abstract 1
- 230000000712 assembly Effects 0.000 abstract 1
- 238000000429 assembly Methods 0.000 abstract 1
- 229940088623 biologically active substance Drugs 0.000 abstract 1
- 239000008280 blood Substances 0.000 abstract 1
- 210000004369 blood Anatomy 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 230000002255 enzymatic effect Effects 0.000 abstract 1
- 230000007071 enzymatic hydrolysis Effects 0.000 abstract 1
- 238000006047 enzymatic hydrolysis reaction Methods 0.000 abstract 1
- 239000008103 glucose Substances 0.000 abstract 1
- 229940125396 insulin Drugs 0.000 abstract 1
- 210000000936 intestine Anatomy 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/28—Insulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
Landscapes
- Health & Medical Sciences (AREA)
- Diabetes (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Endocrinology (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Emergency Medicine (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/RU2011/001061 WO2013100793A1 (ru) | 2011-12-28 | 2011-12-28 | Производное инсулина, обладающее сахароснижающей активностью, и способ его получения |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2014MN01484A true IN2014MN01484A (cs) | 2015-05-01 |
Family
ID=48698085
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN1484MUN2014 IN2014MN01484A (cs) | 2011-12-28 | 2011-12-28 |
Country Status (3)
| Country | Link |
|---|---|
| EA (1) | EA023447B1 (cs) |
| IN (1) | IN2014MN01484A (cs) |
| WO (1) | WO2013100793A1 (cs) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019098869A1 (ru) * | 2017-11-15 | 2019-05-23 | Борис Славинович ФАРБЕР | Фармацевтическая композиция для стимуляции деления стволовых клеток и подавления вирулентности бактерий |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL149337A0 (en) * | 1999-11-05 | 2002-11-10 | Emisphere Tech Inc | Phenoxy carboxylic acid compounds and compositions for delivering active agents |
| CN102227213A (zh) * | 2008-11-28 | 2011-10-26 | 诺沃—诺迪斯克有限公司 | 适合于衍生化的胰岛素肽的口服施用的药物组合物 |
-
2011
- 2011-12-28 EA EA201300207A patent/EA023447B1/ru not_active IP Right Cessation
- 2011-12-28 IN IN1484MUN2014 patent/IN2014MN01484A/en unknown
- 2011-12-28 WO PCT/RU2011/001061 patent/WO2013100793A1/ru not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| EA201300207A1 (ru) | 2014-01-30 |
| WO2013100793A1 (ru) | 2013-07-04 |
| EA023447B1 (ru) | 2016-06-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR077484A1 (es) | Formulacion de acetato de glatiramer de volumen reducido y metodos para su administracion | |
| PH12015500407B1 (en) | Methods of treating hypertriglyceridemia | |
| JP2011241213A5 (cs) | ||
| PE20142319A1 (es) | Tratamiento de esclerosis multiple con combinacion de laquinimod y acetato de glatiramero | |
| EA200901112A1 (ru) | Жидкие композиции, образующие дермальные пленки, для введения лекарственных препаратов в кожу | |
| WO2010129138A3 (en) | Phosphorylated and phosphonated pyrone analogs for therapeutic treatment | |
| WO2011116139A3 (en) | Improved pharmaceutical compositions comprising cck- 8 and methods of delivery | |
| MX2013011174A (es) | Prevencion de hipoglucemia en pacientes con diabetes sacarina de tipo 2. | |
| WO2011118976A3 (en) | Pharmaceutical composition for the prevention or the treatment of non-alcoholic fatty liver disease and the method for prevention or treatment of non-alcoholic fatty liver disease using the same | |
| JP2016539921A5 (cs) | ||
| MX2012000275A (es) | Antagonista de bomba de acido para el tratamiento de enfermedades involucradas en la motilidad gastrointestinal anormal. | |
| US20180104269A1 (en) | Composition for suppressing muscular fatty change | |
| TW201836669A (zh) | 抑制肌纖維變性用組成物 | |
| AU2013219258A1 (en) | Agent for preventing or ameliorating vascular endothelial malfunction | |
| CA2889109C (en) | Composition comprising citrulline and citicoline for improving decline in brain function | |
| WO2006120574A3 (en) | Analogs of 4-hydroxyisoleucine and uses thereof | |
| EA201391063A1 (ru) | Аполипопротеин a-iv в качестве антидиабетического пептида | |
| JP2013170149A (ja) | ヒアルロン酸オリゴ糖を有効成分とする細胞外基質形成促進剤 | |
| IN2014MN01484A (cs) | ||
| WO2011128782A3 (en) | Compositions and methods for treating type ii diabetes and related disorders | |
| CN109379887A (zh) | 基于肌肽-镁络合物的局部用组合物 | |
| Das et al. | Effects of resveratrol on oxidative stress in high fat diet/streptozocin induced diabetic wistar albino rats | |
| Chou et al. | Rapid development of severe skin rash after adding valproic acid in a case of bipolar depression treated with low-dose lamotrigine | |
| JP2012224589A (ja) | 糖質吸収抑制物質 | |
| JP2007031302A (ja) | アディポネクチン産生促進剤、及び代謝異常症候群予防剤 |